Jacob Plieth The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis. Using Car-T therapy in autoimmune disease, beyond its natural habitat of oncology, has gained huge traction of late. But the prospect of having patients undergo burdensome chemo conditioning, while acceptable in cancer, might stifle serious uptake in chronic diseases....
